New immunotherapy drug approved to treat bladder cancer

Posted by  | treatment

A new immunotherapy drug -- the first in its class -- was approved by the Food and Drug Administration last week for bladder cancer. We asked David McConkey, Ph.D., director of the Johns Hopkins Greenberg Bladder Cancer Institute, to explain the significance of this milestone: "The approval of atezolizumab is arguably the most transformative thing(...)

Chemotherapy advances pinpoint mutations for more personalized care

Posted by  | treatment

Chemotherapy is a systemic therapy, and “in the past, lung cancer treatment was really a one-size-fits-all care,” says Russell K. Hales, M.D.  “Thanks to advances in treatment, we’ve been able to transition to more personalized care.  We can assess the tumor for changes that can be targeted with customized therapy, also known as molecular profiling. (...)

Melanoma drug FDA approved

Posted by  | treatment

This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma. Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at the Johns Hopkins Kimmel Cancer Center offered the following insights on the drug's approval: “This approval(...)